German life sciences and pharma company Merck KGaA (MRK: DE) has increased its first-quarter 2016 ales and earnings following the acquisition of US-based pharma equipment maker Sigma-Aldrich.
Shares in the company had risen by 3.4% to 85.47 euros in mid-afternoon trading on Thursday.
It was not just November 2015’s purchase of Sigma-Aldrich, which increased group net sales by 20.5% compared to 1st-qtr 2015, as they went up from $3.36 billion to $4.15 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze